Article
Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.
Endocrinology - 1 May 2016
Walls Gerard V, Stevenson Mark, Soukup Benjamin S, Lines Kate E, Grossman Ashley B, Schmid Herbert A, Thakker Rajesh V
Abstract excerpt
Pasireotide, a somatostatin analog, is reported to have anti-proliferative effects in neuroendocrine tumors (NETs). We therefore assessed the efficacy of pasireotide for treating pancreatic and pituitary NETs that develop in a mouse model of multiple endocrine neoplasia type 1 (MEN1). Men1(+/-) mice were treated from age 12 mo with 40 mg/kg pasireotide long-acting release formulation, or PBS, intramuscularly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.